

Redx Oncology continues to experience dramatic growth

02 Jan 2013

A cancer drug research centre based in Liverpool is looking to fill more than 60 high-value positions having already recruited 60 people since launching in 2012.

Redx Oncology, a private-sector centre for pre-clinical research and novel anti-cancer drug development, launched in April last year and has already created 67 jobs, which span the spectrum from university leavers to senior scientists and project managers.

Positions currently available at Redx Oncology range from junior technicians, to scientists with ten years' experience in industry including senior scientists, senior pharmacologists, and in vitro biology specialists. The company is also offering a range of industrial placements and administrative support roles.

Dr Derek Lindsay, Managing Director at Redx Oncology, said the company had been pleasantly surprised by the level of interest the job vacancies were attracting from talented applicants.

Dr Lindsay said: Redx Oncology is continuing to recruit first-class scientists and professionals from all over the world – boosting Liverpool's knowledge economy and contributing to the growth of the city and the region, and we are delighted to be building on the city's established reputation in cancer care.

The immensely positive response we have had is partly a consequence of the difficult state the pharma industry is in at the moment but it also shows that people are interested in working in the North West and that the region is rapidly developing as a science sector.

The UK pharmaceutical industry has shed over 4,000 science posts in the last two years as major players in the market have closed or consolidated in-house research facilities, but Redx Oncology is bucking the trend as it continues to recruit high-calibre applicants.

Redx Oncology is the first subsidiary of Redx Pharma, an early stage drug development company based in Liverpool, and was awarded a £5.9m grant from the

Government's Regional Growth Fund (RGF) in 2011 to support its development. The company plans to create up to 250 bioscience jobs in the city by 2016.

It's anticipated that a significant number of the new jobs being created by the company will be filled by people relocating to Liverpool and applications have been received from scientists and chemists from all over the UK, Europe and the US keen to take up positions at the centre.

Built around Redx Pharma's extensive pipeline of 40 research drug candidate programs in a wide variety of cancer types, the project aims to deliver a pipeline of experimental drugs, for progression into human clinical trials within five years.

For more information about positions available at Redx Oncology, please visit:
www.redxpharma.com/jobs